Our Contributions
to Trailblazing Science

Our Science

Scientific Publications

Polyglutamine disease:

Accurate Quantification of Mutant and Wild-Type polyQ Proteins Using Simple Western Capillary Immunoassays

Bas Röttgering, Janwillem Testerink, Rudie Weij, Chantal Beekman, Nicole Datson Mol Neurobiol. 2025 May 31. doi: 10.1007/s12035-025-05089-9. PMID: 40450087

High Levels of Mutant Huntingtin Protein in Tear Fluid From Huntington’s Disease Gene Expansion Carriers.

Gijs M, Jorna N, Datson N, Beekman C, Dansokho C, Weiss A, Linden DEJ, Oosterloo M.J Mov Disord. 2024 Apr;17(2):181-188. doi: 10.14802/jmd.24014. Epub 2024 Feb 21.PMID: 38379425

Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide.

Kourkouta E, Weij R, González-Barriga A, Mulder M, Verheul R, Bosgra S, Groenendaal B, Puoliväli J, Toivanen J, van Deutekom JCT, Datson NA.Mol Ther Nucleic Acids. 2019 Sep 6;17:601-614. doi: 10.1016/j.omtn.2019.07.004. Epub 2019 Jul 19.PMID: 31394429

The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain.

Datson NA, González-Barriga A, Kourkouta E, Weij R, van de Giessen J, Mulders S, Kontkanen O, Heikkinen T, Lehtimäki K, van Deutekom JC.PLoS One. 2017 Feb 9;12(2):e0171127. doi: 10.1371/journal.pone.0171127. eCollection 2017.PMID: 28182673

Antisense oligonucleotides:
Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.

van Deutekom J, Beekman C, Bijl S, Bosgra S, van den Eijnde R, Franken D, Groenendaal B, Harquouli B, Janson A, Koevoets P, Mulder M, Muilwijk D, Peterburgska G, Querido B, Testerink J, Verheul R, de Visser P, Weij R, Aartsma-Rus A, Puoliväli J, Bragge T, O’Neill C, Datson NA.Nucleic Acid Ther. 2023 Jun;33(3):193-208. doi: 10.1089/nat.2022.0063. Epub 2023 Apr 10.PMID: 37036788

The Pharmacokinetics of 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy.

Bosgra S, Sipkens J, de Kimpe S, den Besten C, Datson N, van Deutekom J.Nucleic Acid Ther. 2019 Dec;29(6):305-322. doi: 10.1089/nat.2019.0805. Epub 2019 Aug 20.PMID: 31429628

Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in mdx Mice.

Datson NA, Bijl S, Janson A, Testerink J, van den Eijnde R, Weij R, Puoliväli J, Lehtimäki K, Bragge T, Ahtoniemi T, van Deutekom JC.Nucleic Acid Ther. 2020 Feb;30(1):50-65. doi: 10.1089/nat.2019.0824. Epub 2019 Dec 10.PMID: 31821107

Mouse model for DMD:

Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model.

Yavas A, Weij R, van Putten M, Kourkouta E, Beekman C, Puoliväli J, Bragge T, Ahtoniemi T, Knijnenburg J, Hoogenboom ME, Ariyurek Y, Aartsma-Rus A, van Deutekom J, Datson N.PLoS One. 2020 Dec 23;15(12):e0244215. doi: 10.1371/journal.pone.0244215. eCollection 2020.PMID: 33362201

Wes capillary immunoassay:
Low dystrophin variability between muscles and stable expression over time in Becker muscular dystrophy using capillary Western immunoassay.

Koeks Z, Janson AA, Beekman C, Signorelli M, van Duyvenvoorde HA, van den Bergen JC, Hooijmans MT, Alleman I, Hegeman IM, Verschuuren JJGM, V Deutekom JC, Spitali P, Datson NA, Niks EH.Sci Rep. 2021 Mar 15;11(1):5952. doi: 10.1038/s41598-021-84863-w.PMID: 33723284

Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology.

Aartsma-Rus A, Morgan J, Lonkar P, Neubert H, Owens J, Binks M, Montolio M, Phadke R, Datson N, Van Deutekom J, Morris GE, Rao VA, Hoffman EP, Muntoni F, Arechavala-Gomeza V; workshop participants.J Neuromuscul Dis. 2019;6(1):147-159. doi: 10.3233/JND-180357.PMID: 30614809

Scroll to Top
Leadership
Leadership micah mackison

Leadership

Micah Mackison

Chief Executive Officer
Linkedin icon

Mr. Micah Mackison was appointed CEO of Vico Therapeutics in August 2022. Prior to this role, Micah served as Chief Business Officer and Executive Vice President of Strategy and Corporate Development at Locanabio, an RNA-targeted gene therapy company. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, Micah held several leadership positions in corporate development and strategy. He served as Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, where he was focused on neuroscience. Prior to Lundbeck’s acquisition, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s disease.

Earlier in his career, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.